



CASE DM-7029 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV306636650US
Express Mail Label Number

August 12, 2003
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1647

BROWN ET AL.

Examiner: Gucker, S.

APPLICATION NO: 09/454,868

FILED: DECEMBER 3, 1999

FOR: USE OF THE KCNQ2 AND KCNQ3 GENES FOR THE DISCOVERY
OF AGENTS USEFUL IN THE TREATMENT OF NEUROLOGICAL
DISORDERS

RECEIVED
AUG 15 2003
TECH CENTER 1600/2900

MAIL STOP: **Official Draftsperson**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

COMMUNICATION FORWARDING FORMAL DRAWINGS


Sir:

In response to the Notice of Draftsperson's Drawing Review (PTO Form 948) dated July 12, 2000, applicants enclose herewith a new set of formal drawings for FIGS. 1A, 1B, 1C, 1D, 2A, 2B, 2C, 2D, 2E, 3A, 3B, 3C, 3D, 3E, 4A, 4B, 4C, 4D, 4E, 5, 6, 7 (seven sheets total).

Notice of the approval of these drawings is respectfully requested.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-3575



John A. Lamerdin, Ph.D.
Attorney for Applicants
Reg. No. 44,858

Date: August 12, 2003